PYC Therapeutics advances VP-001 for retinitis pigmentosa, gaining FDA insights for its upcoming registrational trial.

The study will be led by principal investigator professor Noemi Lois, MD, PhD, FRCS(Ed), FRCOphth, at Queen’s University Belfast, in over 20 clinical sites, and plans to enroll 264 patients across the UK with severe DME.

Through the program, gene therapies are developed to treat patients with retinitis pigmentosa caused by pathogenic variants in the MERTK gene.

From Nobel laureates to AI-driven research, the Wilmer Eye Institute honors a century of transforming vision science and care.

Kodiak Sciences showcases KSI-101, a potential new treatment for macular edema, at the 2025 IOIS Congress, aiming to better support patient care.

The trial is evaluating KB803 for the treatment and prevention of corneal abrasions in dystrophic epidermolysis bullosa

Qlaris Bio to showcase promising data on QLS-111, a novel glaucoma treatment, at the 2025 World Glaucoma Congress, highlighting its efficacy and safety.

ADX-2191 is an investigational drug candidate from Aldeyra, for the treatment of primary vitreoretinal lymphoma (PVRL), a rare and potentially fatal cancer currently with no current FDA-approved therapy

New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients

Phentolamine Ophthalmic Solution 0.75% is a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, administered as an eye drop for the treatment of presbyopia.

FYB203 has been approved by the US FDA and UK Medicines and Healthcare products Regulatory Agency for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema, macular edema following retinal vein occlusion, and visual impairment due to myopic choroidal neovascularization.

ST-100 shows promise as a fast-acting treatment for dry eye disease, offering rapid relief and unique collagen repair mechanisms.

ForSight Robotics secures $125M to advance its robotic surgery platform, targeting cataract procedures and additional ophthalmic surgeries.

Danegaptide is an oral therapy for early treatment of non-proliferative diabetic retinopathy (NPDR) and associated edema.

Perfuse Therapeutics reveals promising Phase 2 trial results for PER-001, a potential treatment for glaucoma and diabetic retinopathy.

Ixo-vec shows sustained efficacy and reduces injection burden through 4 years in clinical trials